Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Last trade$3.82
Day change-$0.145 (-3.66%)
Day range$3.82 – $4.00
Volume905,803
Market cap$196M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$195.75M
Price / earnings
—
Price / book
0.61×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.31×
Profitability
Earnings per share
-$1.98
Return on assets
-28.61%
Return on equity
-30.59%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
19.88×
Quick ratio
19.88×
Cash ratio
3.73×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$86.6M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ARTV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$5.96M
$4.97M
$5.12M
$4.94M
$5.26M
$4.95M
$5.12M
$4.95M
Research and development
$25.99M
$21.93M
$19.31M
$16.99M
$17.63M
$17.86M
$17.05M
$13.32M
Total operating expenses
$31.95M
$26.89M
$24.43M
$21.93M
$22.9M
$22.81M
$22.17M
$18.27M
Operating income
-$31.95M
-$26.89M
-$24.43M
-$21.93M
-$22.9M
-$22.81M
-$22.17M
-$18.27M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$28.82M
-$25.01M
-$23.52M
-$20.77M
-$21.53M
-$21.25M
-$20.31M
-$16.1M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$28.82M
-$25.01M
-$23.52M
-$20.77M
-$21.53M
-$21.25M
-$20.31M
-$16.1M
Net income attributable to common shareholders
-$28.82M
-$25.01M
-$23.52M
-$20.77M
-$21.53M
-$21.25M
-$20.31M
-$16.1M
EBITDA
-$31.2M
-$26.2M
-$23.76M
-$21.27M
-$22.24M
-$22.17M
-$21.54M
-$17.65M
Basic earnings per share
-$0.56
-$0.63
-$0.95
-$0.85
-$0.88
-$0.87
-$0.83
-$0.66
Diluted earnings per share
-$0.56
-$0.63
-$0.95
-$0.85
-$0.88
-$0.87
-$0.83
-$0.66
Recent news
Company coverage with links to the original publishers.
Artiva Biotherapeutics announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Miralles brings over 20 years of biotech leadership experience and previously served on Artiva's Board. The appointment comes as Artiva prepares for Phase 3 registrational trials of its lead program AlloNK in refractory rheumatoid arthritis, with plans to file a BLA in 2029.
DelveInsight's 2026 report reveals a robust rheumatoid arthritis pipeline with 75+ active players developing 80+ drugs across various clinical stages. The report highlights emerging therapies targeting novel pathways beyond traditional TNF inhibition, including JAK inhibitors, BTK inhibitors, and cell-based immunotherapies. Recent developments include positive Phase III results for Lynk Pharmaceuticals' zemprocitinib, FDA Fast Track designation for Artiva Biotherapeutics' AlloNK, and multiple licensing agreements signaling significant innovation in the RA treatment landscape.
Artiva Biotherapeutics announced that its management will participate in a panel and fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The clinical-stage biotech company is developing cell therapies for autoimmune diseases and cancers, with its lead program AlloNK currently in three ongoing clinical trials for B-cell driven autoimmune diseases.
Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer, bringing over 30 years of global leadership experience in pharmaceuticals, biotechnology, and medical devices. Huston received an inducement grant of 220,000 restricted stock units vesting over four years. The appointment comes as Artiva prepares to receive FDA feedback on its lead program AlloNK and share clinical efficacy data in rheumatoid arthritis in the first half of 2026.
Artiva Biotherapeutics reported treating over 100 patients with AlloNK across autoimmune and oncology indications, receiving FDA Fast Track Designation for refractory rheumatoid arthritis treatment. The company expects initial clinical response data in first half of 2026 and has $123 million cash runway into Q2 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.